Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Second Quarter Financial Results on July 26, 2023 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to...

Wednesday, July 19, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Alkermes plc will hold a conference call on July 26, 2023, to discuss its second quarter financial results. The event will be accessible via webcast and phone for both U.S. and international callers. A replay will be available shortly after the event. Alkermes is focused on developing medicines for various neurological and oncological conditions.
Price reaction · baseline $31.48 (2023-07-18 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is set to report its second quarter financial results.
  • The company continues to develop innovative medicines in neuroscience and oncology.
  • The conference call allows for direct engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , July 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, July 26, 2023 to discuss the company's second quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham , Massachusetts; a research and manufacturing facility in Athlone , Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its Q2 financial results?

Alkermes will report its second quarter financial results on July 26, 2023.

How can I access the Alkermes conference call?

The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers.

Is there a replay available for the conference call?

Yes, a replay of the webcast will be available approximately two hours after the event.

What areas does Alkermes focus on?

Alkermes develops medicines in neuroscience and oncology, among other fields.

ShareAdd on Google
Tags: ALKS Viatris Investor Conferences Healthcare Alkermes financial results conference call biopharmaceuticals neuroscience
Last updated: Jul 19, 2023

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
N1539Phase 2
Hysterectomy →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →